background: ischemic brain strokes consisttwo‑thirdsof strokesand their complications bear a lot of disability for patient and society. in this study, we seek for effect of erythropoietin on ischemic brain stroke’s outcomes according to national institutes of health stroke scale (nihss) changes. methods: this study is a rct (randomized clinical trial). all patients with focal neurologic deficit...

background: stroke is one of the leading causes of mortality and long-term morbidity. the aim of the present study was to determine the ability of baseline serum c-reactive protein (crp) and white blood cell count (wbc) values in predicting the outcome of acute ischemic stroke (ais). methods: this study consisted of patients with first ais referred to poursina hospital, rasht, iran. severity of...

background: serum troponin elevation, characteristic of ischemic myocardial injury, has been observed in some acute ischemic stroke (ais) patients. its cause and significance are still controversial. the purpose of this study is to find determinants of troponin elevation and its relationship with stroke severity and location. methods: between january 2013 and august 2013, 114 consecutive ais pa...

BACKGROUND Scientific guidelines recommend the National Institutes of Health Stroke Scale for ischemic stroke assessment. However, many nurses find "slim" National Institutes of Health Stroke Scale versions or the Glasgow Coma Scale easier to use. OBJECTIVE To compare 3 "slim" versions of the National Institutes of Health Stroke Scale and the Glasgow Coma Scale with the full National Institut...

BACKGROUND AND PURPOSE Stroke is an important cause of death and disability among children. Clinical trials for childhood stroke require a valid and reliable acute clinical stroke scale. We evaluated interrater reliability (IRR) of a pediatric adaptation of the National Institutes of Health Stroke Scale. METHODS The pediatric adaptation of the National Institutes of Health Stroke Scale was de...

BACKGROUND AND PURPOSE The pivotal National Institute of Neurological Disorders and Stroke recombinant tissue plasminogen activator trials excluded patients with ischemic stroke with specific minor presentations or rapidly improving symptoms. The recombinant tissue plasminogen activator product label notes that its use for minor neurological deficit or rapidly improving stroke symptoms has not ...